Mr. Thomas Smeenk reports
HEMOSTEMIX ANNOUNCES COMPLETION OF PHASE II CLINICAL TRIAL SUBJECT FOLLOW UP AND HMTXF UP-LIST
Hemostemix Inc. has completed the phase II clinical trial subject follow-up, as the 65th (final) subject has completed their last follow-up visit. With subject follow-up now completed the company is shifting its focus to completing the data analyses and reporting associated with finalizingits phase II clinical trial. In addition, the company has contracted two additional clinical research associates to assist with the completion of the source document verification process. The entry of all subjects' information into the clinical trial data base and source document verification processes are continuing and this is a crucial preliminary step in finalizing the phase II clinical trial.
Today, FINRA processed a Form 211 relating to the initiation of priced quotations of HMTXF on OTCQB, where the company has reapplied to be listed. The submitting broker-dealer has demonstrated to FINRA compliance with FINRA Rule 6,432 and has met the requirements under that rule to initiate quotation of HMTXF within three business days. FINRA's processing of a Form 211 in no way constitutes FINRA's approval of the security, the issuer, or the issuer's business and relates solely to the submitting broker-dealer's obligation to comply with FINRA Rule 6432 and SEA Rule 15c2-11 when quoting a security.
On April 20, 2021, the United States District Court for the District of Delaware received Aspire Health Sciences LLC's defence statements.
About Hemostemix Inc.
Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the company developed and is commercializing its lead product ACP-01 for the treatment of CLI (critical limb ischemia), PAD (peripheral artery disease), angina, ischemic cardiomyopathy, dilated cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.
On Oct. 21, 2019, the company announced the results from its phase II CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup," which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to 4.5 years.
The company owns 91 patents across five patent families titled: regulating stem cells; in vitro techniques for use with stem cells; production from blood of cells of neural lineage; and automated cell therapy.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.